Table 1.

Demographic and clinical characteristics of the Rochester Epidemiology Project Incident Breast Cancer cohort

		Total cohort N = 1800	BCRL(+) N = 253	BCRL(−) N = 1547
Female	N, %	1789 (99.4%)	250 (98.8%)	1539 (99.5%)
Age at index*	Mean (SD)	61 (13.8)	57 (12.9)	62 (13.9)
Min, max	26, 96	27, 87	26, 96
Age at last follow-up	Mean (SD)	69 (14.3)	68 (14.3)	72 (13.8)
Min, max	31.9, 106.2	34, 100	32, 106
BMI at index
<19	N, %	162 (9.0%)	15 (0.4%)	196 (13%)
19–25	N, %	847 (47.1%)	103 (41%)	694 (45%)
> 25–30	N, %	476 (26.4%)	77 (31%)	400 (26%)
> 30–35	N, %	218 (12.1%)	42 (17%)	176 (11%)
> 35	N, %	89 (4.9%)	15 (6%)	74 (6%)
Side affected by breast cancer
Left	N, %	925 (51.4%)	141 (56%)	784 (51%)
Right	N, %	867 (48.2%)	110 (43%)	757 (49%)
Bilateral	N, %	3 (0.2%)	1 (0.4%)	2 (0.1%)
Stage at diagnosis
I	N, %	1129 (62.7%)	91 (36%)	1038 (67%)
II	N, %	493 (27.4%)	102 (40%)	391 (25%)
III	N, %	111 (6.2%)	56 (22%)	59 (4%)
IV	N, %	30 (1.7%)	3 (1%)	27 (2%)
Breast surgery
Lumpectomy or excisional biopsy	N, %	1027 (57.1%)	111 (44%)	916 (59%)
Modified radical	N, %	512 (28.4%)	96 (38%)	416 (27%)
Modified radical mastectomy with simple mastectomy of uninvolved breast	N, %	223 (12.4%)	42 (17%)	181 (12%)
Axillary surgery†
Complete axillary dissection	N, %	766 (42.6%)	192 (76%)	574 (37%)
Sentinel lymph node biopsy	N, %	699 (38.8%)	56 (22%)	643 (42%)
None	N, %	323 (17.9%)	5 (2%)	318 (21%)
Radiation
Any radiation therapy	N, %	990 (55.0%)	170 (67%)	702 (47%)
Tangent beams	N, %	864 (48.0%)	104 (41%)	760 (49%)
Chest wall	N, %	128 (7.1%)	67 (26%)	61 (4%)
Regional lymph nodes	N, %	244 (13.6%)	99 (39%)	145 (9%)
Any chemotherapy	N, %	1283 (71.3%)	146 (58%)	371 (24%)
Any hormonal therapy	N, %	904 (50.2%)	174 (69%)	730 (47%)

^*Index dates were defined as the date when a new primary breast cancer was pathologically confirmed

^†Categories are not mutually exclusive